Low-dose computed tomography and rapid molecular sputum testing in adults with suspected non-ventilator-associated hospital-acquired pneumonia: the HAP-FAST pilot sequential multiple assignment randomised trial with embedded qualitative and costing s

Background Non-ventilator-associated hospital-acquired pneumonia (nv-HAP) diagnosis is imprecise; chest x-rays (CXR) lack detail and sputum culture delays targeted prescribing. However, the evidence base to support diagnostic improvement is sparse. We assessed the feasibility of a trial of low-dose thoracic CT and rapid molecular testing of sputum. Methods HAP-FAST was a UK NIHR funded, open-label pilot sequential multiple assignment randomised trial with qualitative and costing substudies in four UK hospitals (ClinicalTrials.gov: NCT05483309 ). Using research without prior consent (RWPC) and site-stratified web-based randomisation, clinicians allocated adults with suspected nv-HAP (excluding pregnancy and palliation), before their second antibiotic dose, 1:1 to CT or CXR; participants subsequently treated for nv-HAP with sputum available underwent another 1:1 randomisation to BIOFIRE ® FILMARRAY ® Pneumonia plus Panel (FAPP) with standard microbiology or standard microbiology alone . Feasibility outcomes included recruitment, consent, intervention delivery and data completeness through 90 days. Adverse events were not systematically collected. Analyses were intention-to-treat and descriptive. Results Between June 2023 and March 2024, 220 adults were randomised at stage-1 (109 CT; 111 CXR), reaching target three months early. Of 154/220 (70.0%) subsequently managed as nv-HAP, 92/154 (59.7%) could not produce sputum. 62/154 (40.3%; 28.2% of stage-1) were randomised to stage-2: 31 FAPP and 31 no-FAPP. Allocated imaging was recorded for 75/109 (68.8%) CT and 99/111 (89.2%) CXR participants; 6/31(19.4%) FAPP tests were not completed. Consent for follow-up was obtained for 142/220 (64.5%). Protocol-defined clinical cure was assessable in 1/220 participants. The day-90 resource-use questionnaire was returned by 55/110 participants (50.0%). Qualitative findings supported RWPC but identified needs for staged communication, lower-burden follow-up and improved diagnostic pathways. Excess bed days and readmissions drove costs but data capture requires refinement. Conclusions A definitive trial is plausible only with enhanced RWPC, diagnostic delivery and follow-up pathways, improved sputum procedures, stewardship-aligned outcomes and routine economic data capture.

Authors

Institutions

Publication Details

Journal
medRxiv
Published
2026-11-12
DOI
https://doi.org/10.64898/2026.11.10.26367346
Primary Topic
Nosocomial Infections in ICU
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Low-dose computed tomography and rapid molecular sputum testing in adults with suspected non-ventilator-associated hospital-acquired pneumonia: the HAP-FAST pilot sequential multiple assignment randomised trial with embedded qualitative and costing s

Tom Jenks, Ashley P Jones, Nicola Goddard, Karl Cook et al.
medRxiv
Nosocomial Infections in ICU
preprint

Low-dose computed tomography and rapid molecular sputum testing in adults with suspected non-ventilator-associated hospital-acquired pneumonia: the HAP-FAST pilot sequential multiple assignment randomised trial with embedded qualitative and costing s

Tom Jenks, Ashley P Jones, Nicola Goddard, Karl Cook, Dan Gower Wootton, Natalia Shafiqa, Anica Alvarez Nishio, Frances C. Sherratt, Rohit Bazaz, Danielle McLaughlan, Laura Pilling, C.M. McLeavy, Andrea M. Collins, Karen Irwin, Helen Clay, Simon Timothy Abrams, Stephen Aston, Bridget Young, Erica Thwaite, Ian Powell, Fred Fyles, Lance C. W. Turtle, James Hare, Stephanie Willshaw, Himanshu Pratap Singh, Joseph Wood, Andy Cross, Alex Howard, John Howells, Irene Poku, Sam Trewick, Amy Tao, Emily Lam, Fatima Khalid, Emini Adegbenro, Kurian Kalapurakal, Kerry Edwards, Becci Pearce, Patrick Evans, Anja N Guldemond, Juliette Hucker-Shaw
preprint en

Abstract

Background Non-ventilator-associated hospital-acquired pneumonia (nv-HAP) diagnosis is imprecise; chest x-rays (CXR) lack detail and sputum culture delays targeted prescribing. However, the evidence base to support diagnostic improvement is sparse. We assessed the feasibility of a trial of low-dose thoracic CT and rapid molecular testing of sputum. Methods HAP-FAST was a UK NIHR funded, open-label pilot sequential multiple assignment randomised trial with qualitative and costing substudies in four UK hospitals (ClinicalTrials.gov: NCT05483309 ). Using research without prior consent (RWPC) and site-stratified web-based randomisation, clinicians allocated adults with suspected nv-HAP (excluding pregnancy and palliation), before their second antibiotic dose, 1:1 to CT or CXR; participants subsequently treated for nv-HAP with sputum available underwent another 1:1 randomisation to BIOFIRE ® FILMARRAY ® Pneumonia plus Panel (FAPP) with standard microbiology or standard microbiology alone . Feasibility outcomes included recruitment, consent, intervention delivery and data completeness through 90 days. Adverse events were not systematically collected. Analyses were intention-to-treat and descriptive. Results Between June 2023 and March 2024, 220 adults were randomised at stage-1 (109 CT; 111 CXR), reaching target three months early. Of 154/220 (70.0%) subsequently managed as nv-HAP, 92/154 (59.7%) could not produce sputum. 62/154 (40.3%; 28.2% of stage-1) were randomised to stage-2: 31 FAPP and 31 no-FAPP. Allocated imaging was recorded for 75/109 (68.8%) CT and 99/111 (89.2%) CXR participants; 6/31(19.4%) FAPP tests were not completed. Consent for follow-up was obtained for 142/220 (64.5%). Protocol-defined clinical cure was assessable in 1/220 participants. The day-90 resource-use questionnaire was returned by 55/110 participants (50.0%). Qualitative findings supported RWPC but identified needs for staged communication, lower-burden follow-up and improved diagnostic pathways. Excess bed days and readmissions drove costs but data capture requires refinement. Conclusions A definitive trial is plausible only with enhanced RWPC, diagnostic delivery and follow-up pathways, improved sputum procedures, stewardship-aligned outcomes and routine economic data capture.

medRxiv
Lancashire Teaching Hospitals NHS Foundation Trust (GB), University of Liverpool (GB), Aintree University Hospitals NHS Foundation Trust (GB), Royal Liverpool University Hospital (GB), National Institute for Health and Care Research (GB), Aintree University Hospital (GB), Manchester University NHS Foundation Trust (GB), Warrington and Halton Teaching Hospitals NHS Foundation Trust (GB), Biology of Infection (FR), Warrington Hospital (GB), Wythenshawe Hospital (GB), Royal Preston Hospital (GB), Oldham Council (GB), Health Protection Research Unit in Emerging and Zoonotic Infections at University of Liverpool (GB), Liverpool University Hospitals NHS Foundation Trust (GB)
Good health and well-being
Nosocomial Infections in ICU
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon